Does an elderly patient who previously received the PCV23 (Pneumococcal Conjugate Vaccine) pneumonia vaccine need the PPSV20 (Pneumococcal Polysaccharide Vaccine) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pneumococcal Vaccination for Elderly Patient Previously Vaccinated with PPSV23

An elderly patient who previously received PPSV23 (not PCV23, which doesn't exist) should receive a single dose of PCV20 at least 1 year after the last PPSV23 dose to complete the pneumococcal vaccination series. 1, 2

Understanding the Vaccine Terminology

First, let me clarify: there is no "Pete 23" or "PCV23" vaccine. The patient likely received PPSV23 (23-valent pneumococcal polysaccharide vaccine, also called Pneumovax 23). The newer vaccine being considered is PCV20 (20-valent pneumococcal conjugate vaccine, brand name Prevnar 20), not "P20." 2, 3

Current ACIP Recommendation

For adults aged ≥65 years who previously received only PPSV23, the Advisory Committee on Immunization Practices (ACIP) recommends administering a single dose of PCV20 at least 1 year after the last PPSV23 dose. 1, 2, 3 This is a firm recommendation, not shared decision-making, and represents the preferred approach to provide broader serotype coverage with the immunologic advantages of conjugate vaccines. 1, 3

Why PCV20 After PPSV23?

The rationale for adding PCV20 includes several key advantages:

  • Conjugate vaccines like PCV20 have immunologic advantages over PPSV23, including T-cell dependent responses and immunologic memory that PPSV23 lacks. 1, 3
  • PCV20 provides coverage against 20 pneumococcal serotypes, including 7 additional serotypes beyond PCV13 that account for significant disease burden in older adults. 2, 3, 4
  • Clinical trials demonstrate PCV20 is safe and immunogenic in adults previously vaccinated with PPSV23, with robust immune responses observed regardless of the interval (1-5 years) since prior PPSV23. 5, 6

Timing Requirements

The minimum interval is ≥1 year after the last PPSV23 dose. 1, 2, 3 This interval applies to all elderly patients, regardless of underlying medical conditions. 2, 3 Once this interval has elapsed, PCV20 can be administered at any time. 2, 3

What Happens After PCV20?

Once PCV20 is administered, the pneumococcal vaccination series is complete and no additional pneumococcal vaccines are needed. 2, 3 This is a critical point: do not add PPSV23 after PCV20, as it is unnecessary and not recommended. 3

Special Considerations for High-Risk Patients

If the patient has underlying medical conditions that increase pneumococcal disease risk, PCV20 is even more strongly indicated:

  • Chronic medical conditions (diabetes, chronic heart/lung/liver disease, alcoholism, smoking) increase the benefit of PCV20 vaccination. 1, 3
  • Immunocompromising conditions (chronic renal failure, HIV, malignancies, immunosuppressive therapy, asplenia) make PCV20 particularly important. 1, 3
  • The same ≥1 year interval after PPSV23 applies even for immunocompromised patients. 2, 3

Common Pitfalls to Avoid

  • Do not wait longer than necessary: Once 1 year has passed since PPSV23, the patient should receive PCV20 promptly. 2, 3
  • Do not give additional PPSV23 doses: After receiving PPSV23 at age ≥65 years, no additional PPSV23 doses are recommended. 2
  • Do not add PPSV23 after PCV20: The series is complete with PCV20 alone. 3
  • Do not confuse vaccine names: PPSV23 (polysaccharide) and PCV20 (conjugate) are different vaccine types with different properties. 2, 3

Safety Profile

PCV20 is well-tolerated in adults previously vaccinated with PPSV23. 5, 6 Local reactions (pain, swelling) and systemic events (fatigue, headache) are generally mild to moderate and resolve within days. 5, 6 The safety profile is comparable to other pneumococcal vaccines. 7, 6

Alternative Option (Less Preferred)

While PCV20 is the preferred single-dose option, an alternative is PCV15 followed by PPSV23 ≥1 year later. 2 However, PCV20 is preferred because it simplifies the schedule (one dose instead of two) and provides broader coverage. 2, 3, 7

Bottom Line Algorithm

  1. Confirm vaccination history: Patient received PPSV23 (verify date)
  2. Check timing: Has ≥1 year elapsed since PPSV23?
    • If yes → Administer PCV20 now
    • If no → Wait until 1 year has passed, then give PCV20
  3. Document completion: After PCV20, pneumococcal series is complete
  4. No further doses needed: Do not give additional pneumococcal vaccines after PCV20

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pneumococcal Vaccination Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pneumococcal Conjugate Vaccine Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Recommendations on PCV20 vaccine in adults and at-risk populations.

European respiratory review : an official journal of the European Respiratory Society, 2025

Research

20-Valent Pneumococcal Conjugate Vaccine in Older People.

The Senior care pharmacist, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.